Kidney Week

Abstract: FR-OR039

Sustained Blood Pressure Reduction Following Ultrasound Renal Denervation in Patients with CKD: 12-Month Follow-Up Data from the RDN-CKD Study

Session Information

• Hypertension and Cardiorenal Disease: Novel Mechanisms and Therapeutic Targets
  November 07, 2025 | Location: Room 332A, Convention Center
  Abstract Time: 04:50 PM - 05:00 PM

Category: Hypertension and CVD

• 1602 Hypertension and CVD: Clinical

Authors

• Kannenkeril, Dennis, Universitatsklinikum Erlangen Medizinische Klinik 4 Nephrologie und Hypertensiologie, Erlangen, BY, Germany

Dennis Kannenkeril, MD

• Bytyqi, Venera, Universitatsklinikum Erlangen Medizinische Klinik 4 Nephrologie und Hypertensiologie, Erlangen, BY, Germany

Venera Bytyqi, MD

• Schmid, Axel, Institute of Radiology, Erlangen, Germany

Axel Schmid, MD

• Striepe, Kristina, Universitatsklinikum Erlangen Medizinische Klinik 4 Nephrologie und Hypertensiologie, Erlangen, BY, Germany

Kristina Striepe, MD

• Bosch, Agnes, Universitatsklinikum Erlangen Medizinische Klinik 4 Nephrologie und Hypertensiologie, Erlangen, BY, Germany

Agnes Bosch, MD

• Karg, Marina V., Universitatsklinikum Erlangen Medizinische Klinik 4 Nephrologie und Hypertensiologie, Erlangen, BY, Germany

Marina V. Karg, MD

• Veelken, Roland, Universitatsklinikum Erlangen Medizinische Klinik 4 Nephrologie und Hypertensiologie, Erlangen, BY, Germany

Roland Veelken, MD, DrMed

• Schiffer, Mario, Universitatsklinikum Erlangen Medizinische Klinik 4 Nephrologie und Hypertensiologie, Erlangen, BY, Germany

Mario Schiffer, MD, DrMed, MBA

• Uder, Michael, Institute of Radiology, Erlangen, Germany

Michael Uder, MD

• Schmieder, Roland E., Universitatsklinikum Erlangen Medizinische Klinik 4 Nephrologie und Hypertensiologie, Erlangen, BY, Germany

Roland E. Schmieder, MD, FASN

Background

Renal denervation is considered as a therapeutic option to treat the increased sympathetic nervous system activity in patients with chronic kidney disease (CKD). In a prospective, randomized, sham-controlled, double-blinded clinical trial (RDN-CKD study), we observed a reduction in diastolic blood pressure (BP) in hypertensive patients with stage 3 CKD six months after ultrasound renal denervation (uRDN). We now evaluated BP reduction 12-months after uRDN.

Methods

12-month follow-up data were available for 15 patients (8 patients receiving uRDN immediately and 7 patients receiving uRDN after cross-over) from the centers Erlangen/Nuremberg with CKD stage 3 and uncontrolled hypertension, having undergone uRDN (PARADISE System, ReCor Medical Inc., USA). Office and 24-hour ambulatory BP as well as renal function were assessed 12 months after uRDN.

Results

Twelve months after uRDN, 24-hour systolic and diastolic ambulatory BP decreased by 8.7±12.7 mmHg and 6.5±9.3 mmHg, respectively (Table 1). Office BP measurements showed significant reduction, with mean systolic BP reduced by 11.9±16.4 mmHg and diastolic BP by 7.3±7.9 mmHg. No significant changes were observed in both the number and dosage of antihypertensive medications. Renal function remained stable at 12 months compared to baseline. No safety concerns related to uRDN were identified at the 12-month follow up.

Conclusion

Significant reductions in BP were observed at 12 months following uRDN in patients with stage 3 CKD and uncontrolled hypertension. uRDN may represent a promising adjunctive approach for managing uncontrolled hypertension in patients with moderate CKD.

Funding

• Commercial Support – ReCor Medical

Digital Object Identifier (DOI)

• doi: 10.1681/ASN.2025a5qwnbh0